Navigation Links
ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
Date:6/24/2011

EXTON, Pa., June 24, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a Pediatric Use Marketing Authorization (PUMA) for Buccolam® (midazolam, oromucosal solution), for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years.  If approved by the European Commission, Buccolam would be the first product approved through the centralized PUMA procedure.

Buccolam is oral midazolam provided in a pre-measured, age-specific dose formulation for convenient buccal (i.e. via the cavity between the cheek and gum line) delivery. Buccal midazolam has been shown in four clinical studies to be either comparable or superior in both its effectiveness and speed of onset of action to the current standard treatment, rectally-administered diazepam, for terminating pediatric convulsive epileptic seizures.

"The potential approval of Buccolam would address a major challenge for physicians currently prescribing rectally-administered diazepam for acute seizures, namely that it can be difficult to use and may be socially unacceptable in the community," said Professor Ian Wong, Director of the Centre for Paediatric Pharmacy Research at the School of Pharmacy, University of London. "Midazolam is recommended for treating prolonged acute convulsive seizures according to published treatment guidelines in European countries, and the availability of Buccolam – an oromucosal formulation of midazolam – would be an important, convenient and welcomed alternative to treat seizures in pediatric and adolescent patients."

The CHMP is responsible for issuing the EMA's scientific evaluation and opinions on all Marketing Au
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
2. ViroPharma to Participate in the Jefferies 2011 Global Healthcare Conference
3. ViroPharma Launches Swell, an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema
4. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
5. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
6. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
7. ViroPharma to Participate In Three May Healthcare Investor Conferences
8. ViroPharma to Release 2011 First Quarter Financial Results On April 28, 2011
9. ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR)
10. ViroPharma Launches HAE and Me, A New Online Community to Unite People Living With Hereditary Angioedema
11. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015 Today, UBM China, a ... agreement with Chengdu Tianyi Exhibition Co., Ltd. to jointly ... is to be held concurrently with CWMEE 2016. ... healthcare exhibition family, following MEDTEC China and DENTECH China, ... in west China. It,s also another concrete cooperative project ...
(Date:6/30/2015)... und KOPENHAGEN, Dänemark, 30. Juni 2015 /PRNewswire/ ... Weltmarktführer der klinischen und kommerziellen Produktion von ... heute bekannt, dass das Unternehmen im Rahmen ... der nordamerikanischen Produktionsanlage in Bothell, ... Einweg-Anlage Bioreactor 6Pack™ komplettiert hat. Die Konfiguration ...
(Date:6/30/2015)... 2015  EnteroMedics Inc. (NASDAQ: ETRM ), a ... to treat obesity, metabolic diseases, and other gastrointestinal disorders, ... of 40,229,886 units. Each unit consists of one share ... to purchase one share of common stock, and 0.50 ... of common stock, at a purchase price of $0.87 ...
Breaking Medicine Technology:UBM Joins Chengdu Tianyi to Hold CWMEE 2016 2UBM Joins Chengdu Tianyi to Hold CWMEE 2016 3CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 3
... Inc. (Nasdaq: OPTR ) today announced it expects ... after the NASDAQ Global Market closes on Thursday, March 10, ... that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific ... fourth quarter and full year 2010, as well as provide ...
... CRANBURY, N.J., March 3, 2011 Palatin Technologies, Inc. (NYSE ... Food and Drug Administration (FDA) has cleared Palatin,s request to ... New Drug (IND) application using a subcutaneously administered formulation of ... acute exacerbations of asthma. "We are excited ...
Cached Medicine Technology:Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results 2FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for Asthma 2
(Date:6/30/2015)... ... ... Trenton Health Team has been certified by the New Jersey Department of ... State, serving the greater Trenton community. The ACO pilot is for a three-year ... collaborative structure of THT, bringing together the vast majority of Trenton’s primary and specialty ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... rating in a new video, “Grand Terrace Health Care Center.” Each year, Medicare ... and help patients find the best facility for their needs. Grand Terrace prides ...
(Date:6/30/2015)... ... 2015 , ... University Post-Acute Rehab recently released a video ... center’s patients and their experiences at the facility. Medicare granted University Post-Acute Rehab ... patient attests to the high rating, which is predominantly based on cleanliness, employees, ...
(Date:6/30/2015)... ... June 30, 2015 , ... On June 26, 2015, ... ,” listed five triggers that most people would not expect to cause acne ... toothpaste. The primary causes of acne are clogged pores and bacteria and ...
(Date:6/30/2015)... ... June 30, 2015 , ... After many ... , finally its here, http://www.express-glasses.com is proud to announce its collaboration ... ask about shipping with DHL Express when calling or visiting the express glasses ...
Breaking Medicine News(10 mins):Health News:Trenton Health Team Certified as Medicaid Accountable Care Organization 2Health News:Trenton Health Team Certified as Medicaid Accountable Care Organization 3Health News:Grand Terrace Health Care Center Announces Five-Star Rating in YouTube Video 2Health News:Patients of University Post-Acute Rehab Support Five-Star Rating in New Video 2Health News:A List of 5 Surprising Acne Triggers and the Latest Acne Treatment Options 2Health News:Eyeglasses Online - Express Glasses Announcing New International Shipping Using DHL 2
... By Amanda Gardner HealthDay Reporter , FRIDAY, ... with autism will likely decrease if a new definition of ... year. Doctors aren,t sure what the implications of the ... impact on the lives of people with autism and the ...
... Boston (Jan. 23, 2012) Research to Prevent Blindness ... of Harvard Medical School, a $30,000 Medical Student Eye Research ... Shah. The award will allow Ms. Shah to participate ... Glaucoma Service Director Dr. Louis Pasquale in collaboration with Dr. ...
... Chronic inflammation combines with DNA methylation, a process that ... cancer, scientists at The University of Texas MD Anderson ... of the journal Nature Medicine . The ... lead to better combination therapies for treating and preventing ...
... III colon cancer patients in the general population who receive ... survival when oxaliplatin is added to 5-fluorouracil (5FU), according to ... the National Cancer Institute . Colon cancer is a ... estimated 101,340 cases among Americans in 2011. Roughly one third ...
... Hopkins Center for Injury Research and Policy and the Centers ... increased injury prevention efforts in many of the most popular ... in the United States. Injury is the leading cause of ... health efforts to promote physical activity in kids do not ...
... HealthDay Reporter , FRIDAY, Jan. 20 (HealthDay News) -- ... asthma medication use during pregnancy and common birth defects. ... some rare birth defects and mothers with asthma, and potentially ... whether the problem was a loss of oxygen from less ...
Cached Medicine News:Health News:Experts Weigh Changes to Definition of Autism 2Health News:Experts Weigh Changes to Definition of Autism 3Health News:Inflammatory mediator promotes colorectal cancer by stifling protective genes 2Health News:Inflammatory mediator promotes colorectal cancer by stifling protective genes 3Health News:Study showed oxaliplatin improved colon cancer patient survival 2Health News:Many strategies to increase physical activity for kids lack injury prevention measures 2Health News:Asthma Meds Likely Safe During Pregnancy: Study 2Health News:Asthma Meds Likely Safe During Pregnancy: Study 3
... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
Antelys Peek Lumbar Technologies provides a range of varied heights and angles to correct lumbar lordosis and the associated sagital balance....
Spectrum Dynamics empowers Nuclear Imaging with the SmartR Technology,of the D-SPECT Cardiac Imaging System. The D-SPECT is powered by BroadView Technology to provide unprecedented throughput, whil...
For immediate disabling...
Medicine Products: